主页 > 医学新闻 >
【文摘发布】肝细胞性肝癌在肝移植前两种经动
Authorharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F, Boillot O, Declerck N, Louvet A, Canva V, Romano O, Ernst O, Mathurin P, Pruvot FR.
Source:Liver Transpl. 2007 Apr 10;13(5):665-671.
IF:4.225(2005)
Supraselective transarterial chemoembolization (STACE) more efficiently targets chemotherapy delivered via the feeding arterial branches of the tumor than does conventional transarterial chemoembolization (TACE). However, the hypothesis of its greater efficacy compared with the latter is subject to controversy. The aim of the present study was to compare STACE to conventional TACE in a controlled study of candidates for liver transplantation (LT) for hepatocellular carcinoma (HCC). Patients were matched for factors associated with HCC recurrence and survival. Sixty patients were included: 30 who were treated with STACE and 30 treated with conventional TACE. The 2 groups were similar in terms of matched criteria. In the overall population (uni- and multinodular HCC), there was no marked difference between the 2 groups in 5-year disease-free survival: 76.8% vs. 74.8%. In sensitivity analysis of patients considered to be the best candidates for TACE (uninodular HCC </=5 cm), there was a trend toward significance between STACE and TACE in 5-year disease-free survival: 87% vs. 64% (P = 0.09). The only factor associated with complete tumor necrosis was STACE in the overall population (30.8% vs. 6.9%, P = 0.02), with a similar trend in the subgroup of patients with a single nodule (33.3% vs. 6.7%, P = 0.06), whereas the mean number of procedures was similar in the 2 groups (mean, 1.3 procedures; range 1-5 procedures; P = NS). STACE is more efficient at inducing complete tumor necrosis in the liver. This study observed trends toward improvement in the disease-free survival of patients with uninodular HCC </=5 cm. Future studies focusing on such patients are warranted. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title:Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case-control study.
题目：肝细胞性肝癌在肝移植前两种经动脉介入化疗方法的比较:病倒-对照研究
Author harancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F, Boillot O, Declerck N, Louvet A, Canva V, Romano O, Ernst O, Mathurin P, Pruvot FR.
作者：harancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F, Boillot O, Declerck N, Louvet A, Canva V, Romano O, Ernst O, Mathurin P, Pruvot FR.
Source:Liver Transpl. 2007 Apr 10;13(5):665-671.
来源：《肝脏移植》 2007 Apr 10;13(5):665-671
IF:4.225(2005)
影响因子：4.225(2005)
Supraselective transarterial chemoembolization (STACE) more efficiently targets chemotherapy delivered via the feeding arterial branches of the tumor than does conventional transarterial chemoembolization (TACE).
通过肿瘤营养动脉分支实施的超选择性肝动脉化疗栓塞术（STACE）比常规肝动脉化疗栓塞术（TACE）能更有效地达到化疗的目的。
However, the hypothesis of its greater efficacy compared with the latter is subject to controversy.
然而，这一认为前者比后者更有效的假说引起了争论。
The aim of the present study was to compare STACE to conventional TACE in a controlled study of candidates for liver transplantation (LT) for hepatocellular carcinoma (HCC).
本研究的目的是在一项关于因肝细胞肝癌（HCC）行肝移植（LT）病人的对照研究中对STACE和常规TACE进行比较。
Patients were matched for factors associated with HCC recurrence and survival. Sixty patients were included: 30 who were treated with STACE and 30 treated with conventional TACE. The 2 groups were similar in terms of matched criteria.
依据与HCC复发和生存有关的因素对病人进行筛选。六十例病人入选：30例接受STACE治疗，30例接受TACE治疗。两个组在入选标准上是相同的。
In the overall population (uni- and multinodular HCC), there was no marked difference between the 2 groups in 5-year disease-free survival: 76.8% vs. 74.8%. In sensitivity analysis of patients considered to be the best candidates for TACE (uninodular HCC </=5 cm), there was a trend toward significance between STACE and TACE in 5-year disease-free survival: 87% vs. 64% (P = 0.09).
在总体人群上（单结节和多结节HCC），两组的五年无瘤生存率没有显著差异：分别为76.8%和74.8%。对被认为最适于接受TACE治疗的病人（单结节HCC </=5 cm）进行敏感性分析发现，STACE组与TACE组的五年无瘤生存率有发生差异的趋势：分别为87%和64%（P=0.09）。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-05 05:27
医学,生命科学网